These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 12712470)

  • 1. Improved survival in women with BRCA-associated ovarian carcinoma.
    Cass I; Baldwin RL; Varkey T; Moslehi R; Narod SA; Karlan BY
    Cancer; 2003 May; 97(9):2187-95. PubMed ID: 12712470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
    Tan DS; Rothermundt C; Thomas K; Bancroft E; Eeles R; Shanley S; Ardern-Jones A; Norman A; Kaye SB; Gore ME
    J Clin Oncol; 2008 Dec; 26(34):5530-6. PubMed ID: 18955455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations.
    Levine DA; Argenta PA; Yee CJ; Marshall DS; Olvera N; Bogomolniy F; Rahaman JA; Robson ME; Offit K; Barakat RR; Soslow RA; Boyd J
    J Clin Oncol; 2003 Nov; 21(22):4222-7. PubMed ID: 14615451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.
    Chetrit A; Hirsh-Yechezkel G; Ben-David Y; Lubin F; Friedman E; Sadetzki S
    J Clin Oncol; 2008 Jan; 26(1):20-5. PubMed ID: 18165636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?
    Cass I; Holschneider C; Datta N; Barbuto D; Walts AE; Karlan BY
    Obstet Gynecol; 2005 Dec; 106(6):1327-34. PubMed ID: 16319259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients.
    Tobias DH; Eng C; McCurdy LD; Kalir T; Mandelli J; Dottino PR; Cohen CJ
    Gynecol Oncol; 2000 Aug; 78(2):148-51. PubMed ID: 10926794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data.
    Goffin JR; Chappuis PO; Bégin LR; Wong N; Brunet JS; Hamel N; Paradis AJ; Boyd J; Foulkes WD
    Cancer; 2003 Feb; 97(3):527-36. PubMed ID: 12548593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma.
    Lavie O; Hornreich G; Ben-Arie A; Rennert G; Cohen Y; Keidar R; Sagi S; Lahad EL; Auslander R; Beller U
    Gynecol Oncol; 2004 Feb; 92(2):521-4. PubMed ID: 14766242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with double primary tumors in the breast and ovary- clinical characteristics and BRCA1-2 mutations status.
    Fishman A; Dekel E; Chetrit A; Lerner-Geva L; Bar-Am A; Beck D; Beller U; Ben-Baruch G; Piura B; Friedman E; Struewing JP; Modan B
    Gynecol Oncol; 2000 Oct; 79(1):74-8. PubMed ID: 11006035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations.
    Ramus SJ; Fishman A; Pharoah PD; Yarkoni S; Altaras M; Ponder BA
    Eur J Surg Oncol; 2001 Apr; 27(3):278-81. PubMed ID: 11373105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma.
    Majdak EJ; Debniak J; Milczek T; Cornelisse CJ; Devilee P; Emerich J; Jassem J; De Bock GH
    Cancer; 2005 Sep; 104(5):1004-12. PubMed ID: 16047333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
    Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer.
    Gotlieb WH; Chetrit A; Menczer J; Hirsh-Yechezkel G; Lubin F; Friedman E; Modan B; Ben-Baruch G;
    Gynecol Oncol; 2005 Jun; 97(3):780-3. PubMed ID: 15893369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hereditary ovarian cancer.
    Prat J; Ribé A; Gallardo A
    Hum Pathol; 2005 Aug; 36(8):861-70. PubMed ID: 16112002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of endometrial carcinoma associated with BRCA mutation.
    Levine DA; Lin O; Barakat RR; Robson ME; McDermott D; Cohen L; Satagopan J; Offit K; Boyd J
    Gynecol Oncol; 2001 Mar; 80(3):395-8. PubMed ID: 11263938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
    Laframboise S; Chapman W; McLaughlin J; Andrulis IL
    Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry.
    Werness BA; Ramus SJ; DiCioccio RA; Whittemore AS; Garlinghouse-Jones K; Oakley-Girvan I; Tsukada Y; Harrington P; Gayther SA; Ponder BA; Piver MS
    Int J Gynecol Pathol; 2004 Jan; 23(1):29-34. PubMed ID: 14668547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline mutations of BRCA1 and BRCA2 in Korean sporadic ovarian carcinoma.
    Kim YT; Nam EJ; Yoon BS; Kim SW; Kim SH; Kim JH; Kim HK; Koo JS; Kim JW
    Gynecol Oncol; 2005 Dec; 99(3):585-90. PubMed ID: 16084575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1.
    Rubin SC; Benjamin I; Behbakht K; Takahashi H; Morgan MA; LiVolsi VA; Berchuck A; Muto MG; Garber JE; Weber BL; Lynch HT; Boyd J
    N Engl J Med; 1996 Nov; 335(19):1413-6. PubMed ID: 8875917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.